NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neuland Laboratories has filed a correction to a press release header, changing 'Q4FY26' to 'FY26' after an inadvertent typographical error. The corrected press release contains the company's full year FY26 financial results. For FY26, total income stood at Rs. 2053.1 crore with EBITDA at Rs. 603.4 crore. Q4FY26 showed exceptional growth with total income of Rs. 788.7 crore (up 134.9% YoY), EBITDA of Rs. 319.4 crore (up 448.6% YoY), and EBITDA margin expanding to 40.5% from 17.3% in Q4FY25. The company also highlighted investments in peptide manufacturing and a new R&D centre proceeding as planned.
This is an administrative correction with no financial or operational impact. The underlying FY26 results show strong performance with margin expansion, which could be positive for shareholders.